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A cationic tetrapyrrole inhibits 
toxic activities of the cellular prion 
protein
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Prion diseases are rare neurodegenerative conditions associated with the conformational conversion 
of the cellular prion protein (PrPC) into PrPSc, a self-replicating isoform (prion) that accumulates in 
the central nervous system of affected individuals. The structure of PrPSc is poorly defined, and likely 
to be heterogeneous, as suggested by the existence of different prion strains. The latter represents 
a relevant problem for therapy in prion diseases, as some potent anti-prion compounds have shown 
strain-specificity. Designing therapeutics that target PrPC may provide an opportunity to overcome 
these problems. PrPC ligands may theoretically inhibit the replication of multiple prion strains, 
by acting on the common substrate of any prion replication reaction. Here, we characterized the 
properties of a cationic tetrapyrrole [Fe(III)-TMPyP], which was previously shown to bind PrPC, and 
inhibit the replication of a mouse prion strain. We report that the compound is active against multiple 
prion strains in vitro and in cells. Interestingly, we also find that Fe(III)-TMPyP inhibits several PrPC-
related toxic activities, including the channel-forming ability of a PrP mutant, and the PrPC-dependent 
synaptotoxicity of amyloid-β (Aβ) oligomers, which are associated with Alzheimer’s Disease. These 
results demonstrate that molecules binding to PrPC may produce a dual effect of blocking prion 
replication and inhibiting PrPC-mediated toxicity.
Prion diseases, which include Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI) and 
Gerstmann-Sträussler-Scheinker (GSS) syndrome, can manifest in a sporadic, inherited or transmissible fashion. 
These disorders are associated with the conformational conversion of PrPC, an endogenous cell-surface glycopro-
tein, into PrPSc, a self-propagating, infectious protein (prion). PrPSc replicates by directly binding to PrPC, and 
causing its conformational rearrangement into new PrPSc molecules1. A great deal of evidence indicates that PrPSc 
may exist as an ensemble of conformers (referred to as prion strains), eliciting different neuropathological effects2. 
Prion strains represent a critical problem for treating prion diseases. In fact, several potent anti-prion compounds 
are strain-specific3–5. Moreover, acquisition of resistance to therapeutic treatments, reported in prion-infected 
cells and mice, has been attributed to the appearance of drug-resistant prion strains6,7. An additional confounding 
factor for drug discovery in prion diseases is related to the pathogenicity of PrPSc. It is becoming increasingly evi-
dent that PrPSc is not neurotoxic per se, and instead requires functional PrPC at the neuronal surface to deliver its 
detrimental effects8–10. Thus, PrPC appears to play two crucial roles in prion diseases, by passively sustaining prion 
replication, and actively mediating PrPSc toxicity. Analogously, several studies have shown that PrPC may act as 
a selective, high affinity and toxicity-transducing receptor for Aβ oligomers, which are thought to be responsible 
for the synaptotoxicity underlying the cognitive decline in Alzheimer’s disease11. An additional study reported 
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that PrPC may also mediate the cytotoxicity of other β -sheet-rich protein aggregates12. These data suggest that, 
in addition to PrPSc, multiple disease-associated protein aggregates may use PrPC to deliver their detrimental 
effects. This conclusion has therapeutic relevance. Compounds targeting PrPC, and blocking its transducing activ-
ity, may provide potential benefits for prion diseases, and possibly other neurodegenerative disorders13. Various 
chemical classes have been reported to bind PrPC. However, a careful evaluation of data reproducibility, as well 
as consistency between binding affinity and biological activity, restricted the number to a few14,15. Among these, 
an iron tetrapyrrole derivative [Fe(III)-TMPyP, Fe(III)-meso-tetra(N-methyl-4-pyridyl)porphine] was shown to 
interact with the C-terminal, structured domain of PrPC, and to inhibit prion replication in vitro and in cells16,17. 
The compound, or highly similar porphyrins, also significantly prolonged survival in prion-infected mice18–20. In 
this study, in addition to reproducing and extend PrPC-binding and anti-prion properties of Fe(III)-TMPyP, we 
report unexpected evidence regarding the activity of this compound in different cell-based assays for PrPC-related 
toxicity.
Results
Fe(III)-TMPyP binds to mouse, recombinant PrPC. The cationic tetrapyrrole Fe(III)-TMPyP (Fig. 1A) 
was previously shown to bind human recombinant PrPC, and inhibit the replication of a mouse prion in vitro 
and in cells, by acting as a pharmacological chaperone for the native fold of the protein17. Here, we sought to 
Figure 1. Fe(III)-TMPyP binds to PrPC. (A) Structure of Fe(III)-TMPyP; (B) Fe(III)-TMPyP but not GN8, 
binds to recombinant PrPC, as assayed by equilibrium dialysis. A 50 μM aliquot of the indicated compounds and 
recombinant proteins were placed in the assay and sample chambers, respectively. The chambers were separated 
by a 5,000 molecular weight cut-off membrane. Samples were left to equilibrate at room temperature for 1 day 
with gentle rocking. The concentration of each compound was quantified using UV-visible spectroscopy with 
buffer background subtracted. Statistics (by student t-test) was as follow: for GN8, Buffer vs BSA, p = 0.233; 
Buffer vs PrPC, p = 0.394; for Fe(III)-TMPyP, Buffer vs BSA, p = 0.129; Buffer vs PrPC, p = 3.9 × 10−5 (*).  
(C) Fe(III)-TMPyP binds to recombinant PrPC, as detected by DMR. Different concentrations of Fe(III)-
TMPyP were added to label-free microplate well surfaces (EnSpire-LFB HS microplate, Perkin Elmer) on which 
full-length mouse recombinant PrPC had previously been immobilized. Measurements were performed before 
(baseline) and after (final) adding the compound. The response (pm) was obtained subtracting the baseline 
output to the final output signals. The output signal for each well was obtained by subtracting the signal of the 
protein-coated reference area to the signal of uncoated area. The data (red dots) were fitted (black line) to a 
sigmoidal function using a 4 parameter logistic (4PL) nonlinear regression model; R2 = 0.96; p = 4.4 × 10−3.  
(D) SPR analyses of Fe(III)-TMPyP interaction with PrPC. Starting at time 0, the indicated concentrations 
of Fe(III)-TMPyP were injected for 200 sec over sensor chip surfaces (GL-H chip, Bio-Rad) on which 16.000 
resonance units (RU) of full-length, mouse recombinant PrPC had previously been captured by amine coupling. 
The chip was then washed with PBST buffer alone to monitor ligand dissociation. Sensorgrams show Fe(III)-
TMPyP binding in RU. The data were obtained by subtracting the reference channels, and best fitted by 
the Langmuir equation, assuming a heterogeneous ligand on the surface. Kinetic constants were as follow: 
ka = 5.95 × 102 1/Ms; kd = 7.18 × 10−4 1/s; Kd = 1.21 μM; Rmax = 500.57 RU.
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confirm directly that Fe(III)-TMPyP is also able to bind full-length, mouse recombinant PrPC. First, we employed 
equilibrium dialysis, a technique originally used to detect binding of Fe(III)-TMPyP to human PrPC. The assay 
is based on the ability of a small molecule to equilibrate between two chambers, one filled with just buffer (assay 
chamber), and the other containing the target protein (sample chamber), separated by a membrane permeable 
only to the small molecule. As expected, Fe(III)-TMPyP (10 μM) equilibrated equally between the two chambers 
when the sample chamber contained no polypeptide, or BSA (10 μM). Conversely, when mouse recombinant 
PrPC (10 μM) was added to the sample chamber, we observed a marked (>75%) decrease in the concentration of 
Fe(III)-TMPyP in the assay chamber, indicating that the compound interacted with PrPC (Fig. 1B). No binding 
was observed for GN8, a small molecule originally claimed to bind PrPC 21, but that also failed to bind recombi-
nant PrPC in following studies17. Next, we employed dynamic mass redistribution (DMR), a label-free, biophysical 
technique previously employed to detect molecular interactions at the equilibrium (Fig. 1C)22,23. Recombinant, 
mouse PrPC was immobilized on the surface of a 384-well, label-free microplate by amine-coupling chemistry. 
The plate was then incubated for 3 hr at room temperature to obtain optimal binding conditions, before adding 
different concentrations of Fe(III)-TMPyP (0.1–500 μM). Binding to PrPC was monitored after an additional 
30 min of incubation. We observed dose-dependent binding of Fe(III)-TMPyP to PrPC in the concentration range 
of 0.1–1 μM, after which binding appeared to saturate. Experimental controls, used to normalize the signals, 
included empty surfaces (built in each microplate well) and buffer injections. Interestingly, the affinity constant 
obtained by DMR (Kd = 0.63 μM) was highly consistent with the inhibitory concentration at 50% (IC50) of 
Fe(III)-TMPyP and closely related compounds against prion replication in cell cultures (0.5–1 μM)16.
Finally, we employed SPR, another biophysical technique previously used to characterize association and 
dissociation constants in a kinetic manner (Fig. 1D). Recombinant PrPC was immobilized on the surface of an 
SPR chip, as confirmed by binding of an anti-PrP antibody (not shown). We then monitored the association and 
dissociation of Fe(III)-TMPyP (0.1–10 μM) over the course of ~18 min. Non-specific interactions were accounted 
by subtracting signals from channels where only buffer was injected, or no polypeptides were immobilized. The 
sensorgrams were best fitted by a Langmuir binding model for a heterogeneous ligand, likely reflecting the pres-
ence of recombinant PrPC molecules immobilized in different orientations onto the chip surface. These analyses 
indicated a dissociation constant for the interaction of Fe(III)-TMPyP to recombinant PrPC of 1.21 μM. Once 
again, we failed to observe detectable binding (>100 μM) for GN8 (not shown). Collectively, these data confirmed 
that Fe(III)-TMPyP binds to recombinant mouse PrPC in the low micromolar range. Of note, both DMR and 
SPR analyses revealed that Fe(III)-TMPyP binds also to BSA, used in some experiment to monitor non-specific 
interactions, at concentrations around 10 μM (not shown).
Fe(III)-TMPyP inhibits the replication of different prion strains. It was previously reported that 
Fe(III)-TMPyP inhibits the replication of the Rocky Mountain Laboratory (RML) prion strain in cells16,17. Since 
the compound has been proposed to act as a pharmacological chaperone, stabilizing the native conformation 
of PrPC, its inhibitory effect should theoretically be observed against multiple prion strains. In order to test this 
hypothesis, we first employed N2a cells, a sub-clone of murine neuroblastoma cells, infected with the 22L mouse 
prion strain. 22L-N2a cells were exposed for 72 h to different concentrations of Fe(III)-TMPyP (1–10 μM), or 
vehicle control, and the levels of proteinase K (PK)-resistant PrPSc were measured by Western blot. We con-
firmed that treatment with Fe(III)-TMPyP reduced 22L-prion loads in a dose-dependent fashion, with an IC50 
of 1.61 ± 0.79 μM (Fig. 2). No cytotoxicity was observed at the active concentrations (not shown; lethal dose 50% 
was higher than 100 μM).
To confirm that Fe(III)-TMPyP exerts its anti-prion effects in a strain-independent fashion, we employed the 
protein misfolding cyclic amplification (PMCA) reaction, a widely established in vitro assay for evaluating the 
propagation of prions in a test tube (Fig. 3)24. The methodology is based on a PrPSc-triggered conversion of PrPC 
by repetitive cycles of incubation and sonication. Brain lysates from transgenic (Tg) mice expressing ovine PrP 
(called Tg338) were used as a substrate for the amplification of scrapie prions, used as seeds (Dawson isolate). 
Different dilutions of scrapie (from 1:10 to 1:163, 840) were pre-incubated with Fe(III)-TMPyP (500 μM) or vehi-
cle (control) and subjected to a single round of PMCA. The levels of PrPSc in each sample were then estimated by 
detecting PK-resistant PrP molecules by Western blot. In control samples, we observed robust PrPSc amplification 
at every dilution (Fig. 3A). Conversely, in presence of Fe(III)-TMPyP, PrPSc was barely detectable only at the 
lower dilution. We concluded that the compound exhibited a potent inhibitory activity toward the amplification 
of PrPSc. To further substantiate this observation, we employed a PMCA assay specifically designed to rapidly test 
the inhibitory activity of small compounds. In this assay, 1:100 dilutions of bank vole-adapted prion strains are 
used as seeds for bank vole brain substrates, subjected to a single overnight PMCA round, in presence or absence 
of the test compound. By using this alternative PMCA protocol, we were able to generate a >10 fold amplification 
of PrPSc in 16 hours. At first, we determined the amplification factor of an Italian vole-adapted scrapie strain in 
presence of Fe(III)-TMPyP (500 μM) or vehicle control (Fig. 3B). In these conditions, Fe(III)-TMPyP showed 
strong inhibitory activity toward the amplification of vole-adapted PrPSc (amplification factors dropped from 
14.43 ± 3.47 to 1.46 ± 0.83). Of note, exposure to Fe(III)-TMPyP did not alter the detection of PK-resistant PrP 
molecules by Western blot, as evidenced by the similar levels of PrPSc detected in the frozen (F) controls (Fig. 3B, 
lanes 1 and 3). We tested the molecule also against two additional bank vole-adapted scrapie strains, distinct 
from the Italian strain [namely, a UK strain, derived from the sheep isolate SCR125, and vole-adapted CH164126]. 
Fe(III)-TMPyP (500 μM) showed a comparably potent inhibitory effect against the three different strains (not 
shown). Finally, we performed dose-response experiments to estimate the IC50 of Fe(III)-TMPyP against the 
Italian vole-adapted scrapie strain (Fig. 3C). We found that the compound was already active at low micromolar 
concentrations (IC50 = 6.21 + /− 1.9 μM). However, statistical significance was observed only at higher concentra-
tions (50–100 μM), possibly due to the high variability of the assay. Taken together, these data strongly supported 
the notion that Fe(III)-TMPyP exerts its anti-prion activity in a strain-independent fashion.
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Fe(III)-TMPyP inhibits the cytotoxic effects of a mutant PrP. We have previously reported that 
PrPC molecules carrying deletions or point mutations in the conserved central region (CR) are associated with 
a spontaneous ion channel activity that critically depends on the conserved polybasic sequence at the extreme 
N-terminus27,28. These currents can be easily recorded by patch clamping techniques. Since Fe(III)-TMPyP binds 
directly to PrPC, we tested whether this compound could alter the ion channel activity of ∆CR PrP (deleted for 
residues 105–125), the most active among the channel-forming mutants. As expected, HEK293 cells express-
ing ΔCR PrP displayed large, spontaneous inward currents that were absent in cells expressing wild-type (WT) 
PrP (Fig. 4). Importantly, the currents were dose-dependently silenced by treatment with Fe(III)-TMPyP 
(IC50 = 1.7 μM). The compound showed no effects at the highest concentration (50 μM) in WT cells.
As a possible consequence of its channel-forming activity, expression of ∆CR PrP has been shown to hyper-
sensitize various cultured cell lines to the toxicity of cationic antibiotics29. These include Zeocin, a member of 
the bleomycin/phleomycin family, and aminoglycoside G418. This peculiar property was previously exploited 
to develop a drug-dependent cellular assay (DBCA) for studying the toxicity of ∆CR PrP30. Here, we used the 
DBCA to confirm the inhibitory effect of Fe(III)-TMPyP. As expected, ΔCR-expressing HEK293 cells exposed to 
Zeocin (500 μg/mL; Fig. 5A) or G418 (500 μg/mL; not shown) for 72 h showed strongly reduced viability (< 30%), 
as assayed by MTT. Consistent with patch-clamp recordings, co-treatment with Fe(III)-TMPyP (0.1–10 μM) pro-
duced a robust, dose-dependent rescue of antibiotic-induced cell death (IC50 = 3.26 ± 2.12 μM; Fig. 5B). The com-
pound failed to rescue the non-specific cell death induced by high concentrations of Zeocin (up to 2 mg/mL) in 
WT cells (Fig. 5C). Fe(III)-TMPyP was also not toxic to control cells (up to 50 μM) and did not significantly alter 
ΔCR PrP expression (Fig. 6A) or cell surface localization (not shown). These results indicated that Fe(III)-TMPyP 
acts a specific inhibitor of ∆CR PrP activity.
Figure 2. Fe(III)-TMPyP inhibits the replication of 22L prions in cell cultures. 22L-infected N2a cells 
were incubated with various concentrations (indicated) of Fe(III)-TMPyP for 72 h. The total amount of PrPSc 
was estimated in cell lysates by detecting the amount of protease K (PK)-resistant PrP by Western blot (upper 
panel), and quantifying signals by densitometric analysis (graph in the lower panel). Total PrP signal was 
revealed with anti-PrPC antibody 6D11. Statistically-significant differences (*) between Fe(III)-TMPyP-treated 
and the untreated samples was estimated by student t-test: [1 μM], p = 0.034; [3 μM], p = 6.1 × 10−6; [10 μM], 
p = 3.4 × 10−7.
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Fe(III)-TMPyP blocks the synaptotoxicity of Aβ oligomers. The interaction between PrPC and Aβ oli-
gomers has been shown to trigger a rapid, toxic signaling pathway involving the transient activation of the tyros-
ine kinase Fyn, and ultimately producing a dysregulation of NMDA receptors, excitotoxicity, and dendritic spine 
loss11,31,32. Therefore, we tested whether Fe(III)-TMPyP could also inhibit the toxicity of Aβ oligomers mediated 
by PrPC. In a first set of experiments, we exposed primary cultures of postnatal mouse hippocampal neurons to 
Aβ oligomers (3 μM) for 20 minutes. Consistent with previous studies32, we found that the oligomers induced 
a quick, transient and robust (~2 fold) increase of phosphorylated Fyn (Fig. 7A). The phospho-SFK antibody 
used here detects pY416 in several SFKs, but previous studies demonstrated that PrPC-dependent activation of 
kinases is specific for Fyn32. Pre-incubation for 20 minutes with Fe(III)-TMPyP (10 μM) completely prevented Aβ 
effects, maintaining Fyn phosphorylation to normal levels (Fig. 7A). As observed in cultured cells, the compound 
showed no effect on PrPC expression (Fig. 6B). Consistent with previous reports32, no significant increase in Fyn 
phosphorylation was detected in hippocampal neurons derived from PrP knockout (KO) mice, upon treatment 
with Aβ oligomers and/or Fe(III)-TMPyP (Fig. 7B). Next, we tested the ability of Fe(III)-TMPyP to block Aβ 
oligomer-dependent synaptotoxicity (Fig. 8). Primary hippocampal neurons were incubated for 3 hours with Aβ 
oligomers (3 μM). Consistent with previous reports33, we observed a decrease of several post-synaptic markers, 
as evaluated by Western blot of the Triton-insoluble fractions. Post-synaptic markers affected by Aβ oligomer 
treatment included subunits of the glutamate receptors NMDA (GluN2A, GluN2B, decreased to 40.9 ± 7.5 and 
42.1 ± 2.3%, respectively) and AMPA (GluA1 and GluA2, decreased to 57.8 ± 4.3 and 36.1 ± 4.9%), as well as 
the post-synaptic density protein 95 (PSD-95; reduced to 51.3 ± 6.3%). In absence of Aβ oligomers, the levels 
of these proteins were not significantly changed upon treatment with Fe(III)-TMPyP (not shown). However, 
Figure 3. Fe(III)-TMPyP inhibits in vitro replication of vole-adapted scrapie. (A) Tg338 brain homogenates, 
seeded with indicated dilutions of Dawson isolate scrapie strain, were subjected to a single, 48 hr-long round of 
standard PMCA, upon incubation with Fe(III)-TMPyP (500 μM) or vehicle (VHC) control. Amplified samples 
were digested with PK and analyzed by Western blot using monoclonal antibody SAF83. Fe(III)-TMPyP 
showed an inhibitory activity toward prion amplification of at least 16,000 folds. CTR: Normal, unseeded and 
untreated brain homogenate. Molecular markers are KDa. (B) Brain homogenates from terminally ill voles 
infected with an Italian vole-adapted scrapie strain were diluted 1:10 (F, lanes 1 and 3) or 1:100 (A, lanes 2 
and 4) in PMCA substrate in presence of vehicle (VHC, lanes 1–2) or 500 μM Fe(III)-TMPyP (lanes 3 and 4). 
Samples diluted 1:100 were subjected to a single PMCA round, while those diluted 1:10 were kept frozen and 
used to determine the amplification factor. Samples were PK-digested and analyzed by Western Blotting with 
antibody SAF84. (C) A similar experiment was carried out, in triplicate (n = 3), using different concentrations 
of Fe(III)-TMPyP (1–100 μM). The graph illustrates mean amplification factors (± standard error) obtained 
with increasing concentrations of Fe(III)-TMPyP or vehicle alone. Statistical differences (*) between Fe(III)-
TMPyP and vehicle control were estimated by student t-test: [1 μM], p = 0,476; [5 μM], p = 0,273; [10 μM], 
p = 0,073; [50 μM], p = 0,047; [100 μM], p = 0,019.
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pre-treatment with Fe(III)-TMPyP for 20 minutes prior to incubation with Aβ oligomers significantly rescued the 
levels of all the post-synaptic markers (GluN2A and GluN2B levels were increased to 97,7 ± 16,3 and 92,6 ± 15%; 
GluA1 to 108.5 ± 25.9 GluA2 both to 106.7 ± 28.4%; and PSD95 to 112.2 ± 18.6%). The level of a control pro-
tein (actin) was not affected by either Aβ oligomers or Fe(III)-TMPyP. Collectively, these data demonstrate that 
Fe(III)-TMPyP inhibits the synaptotoxic effects of Aβ oligomers mediated by PrPC.
Discussion
Mounting evidence suggests that PrPSc may be an inconvenient pharmacological target34. Indeed, several mol-
ecules identified as potent anti-prion agents in cells, have proven to be strain-dependent, showing therapeutic 
efficacy in vivo only against specific prion strains5,35. To further complicate the matter, poorly defined misfolded 
PrP intermediates, rather than fully aggregated PrPSc isoforms, are emerging as potential pathological species 
in prion diseases36,37. We and others have been interested to explore an experimental strategy that may over-
come these problems by directly targeting PrPC 13,38. Small molecules binding to PrPC with sufficiently high affin-
ity could theoretically stabilize its tertiary structure enough to disfavor the generation of any misfolded state 
or pathogenic PrP conformer. Moreover, since they target the native precursors of prion-induced misfolding 
reactions, rather than the aggregated end-products, PrPC-directed compounds should theoretically be effective 
independently of the prion strain phenomenon. A similar strategy applied to transthyretin, a protein associated 
with familial amyloid polyneuropathy, recently led to the development of Tafamidis, an approved drug for these 
disorders39,40. Multiple chemical classes have been reported in the literature to bind PrPC. These include tricyclic 
phenothiazines, 2,4-diarylthiazoles, quinacrine, a compound named GN8, pyridine-3,5-dicarbonitriles, tetra-
pyrroles, and few others15,41. Some of these, such as quinacrine, have been shown to bind PrPC in a non-specific 
fashion42. Others, like GN8, have not been confirmed to be PrPC ligands in following publications (we also 
failed to detect binding of GN8 to mouse PrPC in this study)17. Additional molecules were shown to bind PrPC 
at biologically-irrelevant concentrations. For example, binding to PrPC for promazine or chlorpromazine was 
observed by using millimolar concentrations of compounds43. However, these molecules are effective against 
prion replication in cell cultures at low micromolar concentrations, making it difficult to reconcile their biological 
activity with their putative, PrPC-directed mode of action44,45. In this study, we sought to characterized the bio-
logical properties of a synthetic, iron-complexed porphyrin named Fe(III)-TMPyP. This compound was reported 
to interact with a relatively large region in the C-terminal, structured domain of PrPC, in correspondence to a 
pocket near the C-terminus of helix-317. Fe(III)-TMPyP was shown to act as a pharmacological chaperone for 
PrPC, lowering the ground state of its native conformation, and inhibiting prion-induced misfolding in vitro and 
in cell cultures. Importantly, binding affinity for PrPC and active concentrations against prion propagation were 
Figure 4. Fe(III)-TMPyP inhibits ionic currents induced by ΔCR PrP. (A) Whole‐cell patch clamp recording 
from HEK293 cells expressing either WT or ΔCR PrP, at a holding potential of − 80 mV. Fe(III)-TMPyP at the 
reported concentrations was added to the dish at the time indicated by the arrows. (B) Inward currents recorded 
from WT or ΔCR PrP HEK293 cells were plotted as the percentage of total time the cells exhibited currents 
≥ 450 pA (mean ± S.E.M., n ≥ 5 cells), at a holding potential of − 80 mV. Statistically-significant differences (*) 
between Fe(III)-TMPyP-treated and the untreated ΔCR cells were estimated by student t-test: [1], p = 0.036; [3], 
p = 0.0016; [10], p = 0.0014; [50], p = 0.005.
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comparable (both in the low micromolar range). We confirmed binding of Fe(III)-TMPyP to recombinant PrPC 
by three different techniques. These included equilibrium dialysis, which was the primary screen that led to the 
original identification of Fe(III)-TMPyP binding to PrPC, and two complementary biophysical techniques (DMR 
and SPR). The latter allowed us to estimate the binding affinity of Fe(III)-TMPyP for PrPC in the low micromolar 
concentration range, consistent with previously reported affinity constants17. We also detected an interaction 
between Fe(III)-TMPyP and BSA when the compound was tested by DMR and SPR, at concentrations slightly 
higher than those active in biological assays. Curiously, this was not observed by equilibrium dialysis. The pos-
sible, non-specific interaction with such an abundant plasma protein, together with the unlikelihood that the 
compound may cross the blood brain barrier, could negatively affect the therapeutic potential of Fe(III)-TMPyP 
upon systemic administration. Therefore, extensive pharmacokinetic profiling, coupled to chemical optimization 
efforts, will be required to design effective drug-like derivatives of Fe(III)-TMPyP.
We also tested the hypothesis that Fe(III)-TMPyP inhibits prion propagation in a strain-independent man-
ner. The compound was challenged against the 22L prion strain in neuroblastoma cells, and four different sheep 
prion strains by using two alternative PMCA protocols. We found comparable IC50 values for the activity of 
Fe(III)-TMPyP in cells and PMCA (1.61 μM and 6.21 μM, respectively). However, the inhibitory effect of the 
compound was much less reliable in the PMCA assay (statistically significant effects were detected only above 
50 μM). Reasons for such discrepancy could be related to the stability of the compound in brain lysates under 
heavy sonication conditions, or simply to the higher variability of the PMCA assays. In any case, these data con-
firm the ability of the compound to bind PrPC at biologically-relevant concentrations, and exert its inhibitory 
activity against multiple prion strains.
Based on the observation that Fe(III)-TMPyP is a PrPC ligand, we were prompted to test the possibility that 
this compound may exert specific effects on PrPC activity. Despite two decades of intense investigation, the phys-
iological function of PrPC is still uncertain10,46. However, several direct or indirect effects of PrPC expression 
have been described in cells and mice. One of these is the ability of WT PrPC to rescue the neurodegenerative 
Figure 5. Fe(III)-TMPyP inhibits the drug-hypersensitizing effect of ΔCR PrP. (A) The DBCA was used to 
evaluate the anti-ΔCR PrP effects of Fe(III)-TMPyP. Stably transfected WT or ΔCR HEK293 cells carrying the 
hygromycin B resistance cassette were plated in 24-well plates and incubated in medium containing 500 μg/mL 
of Zeocin, for 48 h at 37 °C. The picture shows an example of treated vs untreated wells after MTT assay. (B) The 
bar graph shows a quantification of the dose-dependent, rescuing effect of Fe(III)-TMPyP. Average values were 
obtained from a minimum of 4 independent experiments (n = 4), and expressed as a percentage of cell viability 
in untreated cells. Statistically-significant differences (*) between Fe(III)-TMPyP-treated and untreated cells 
was estimated by student t-test: [0.1], p = 0.1582; [0.3], p = 0.0659; [1], p = 1.67 × 10−4; [3], p = 2.19 × 10−4; 
[10], p = 3.37 × 10−6. (C) Fe(III)-TMPyP did not rescue the toxicity of Zeocin in WT PrP-expressing cells. 
The DBCA was adapted to test the toxicity of Zeocin in HEK293 cells stably expressing WT PrP, and evaluate 
the potential rescuing effect of Fe(III)-TMPyP. Cells were plated in 24-well plates and incubated in medium 
containing different concentrations (0–2.000 μg/mL) of Zeocin, for 72 h at 37 °C, in presence (1–10 μM) or 
absence of Fe(III)-TMPyP. Average values were obtained from a minimum of 3 independent experiments 
(n = 3), and expressed as percentage of cell viability of Zeocin-untreated cells.
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phenotype caused by particular PrP mutants47. In an attempt to investigate the role of PrPC in synaptic function, 
and how this activity could be connected to prion neurotoxicity, we and others have studied mutant forms of PrP 
carrying deletions in the highly conserved central region of the protein27,48,49. One of these mutants, referred to as 
ΔCR PrP (Δ105–125), has been shown to be soluble, protease-sensitive, and to have the same cellular localization 
pattern of WT PrPC 50. However, in contrast to PrPC, expression of ΔCR PrP in transgenic mice causes cerebellar 
degeneration and neonatal death27. The neurotoxic mechanism activated by ΔCR PrP may relate to its ability to 
induce ionic currents at the plasma membrane. These currents are the most likely cause of the hypersensitivity 
to cationic antibiotics observed in a variety of ΔCR PrP-expressing cells29. In vivo, ΔCR PrP currents alter the 
physiological homeostasis of glutamatergic synapses, causing the activation of an excitotoxic cascade, and early 
degeneration of the granule neurons in the cerebellum51. Importantly, the entire spectrum of detrimental effects 
caused by ΔCR PrP can be dose-dependently suppressed by the co-expression of WT PrPC, suggesting that the 
mutant and WT proteins could be interacting at a functional level10. ΔCR PrP has another intriguing property 
that suggests its relevance for PrPC biology. Its activity has been shown to be dependent on two stretches of 
poly-basic residues in the N-terminal, flexible tail of the protein (23–28 and 95–105)28. Strikingly, these two sites 
are also directly involved in the interaction between PrPC and Aβ oligomers, and at least two additional protein 
aggregates12,52. Together, these data suggest the intriguing possibility that the aberrant activity of ΔCR PrP, and 
the neurotoxic signaling activated by Aβ oligomers, could be connected to the physiological function of PrPC 10,14. 
In this study, we show that Fe(III)-TMPyP blocks ΔCR PrP activity in a dose-dependent fashion in two different 
cellular assays. These included the suppression of ΔCR PrP-induced currents, as measured by whole-cell patch 
clamp, and the inhibition of the hypersensitivity to cationic antibiotics conferred by the mutant, as evaluated by 
DBCA. Moreover, we found that pre-incubation with Fe(III)-TMPyP protects primary hippocampal neurons to 
the Fyn-mediated, PrPC-dependent synaptotoxicity of Aβ oligomers. These protective effects of Fe(III)-TMPyP 
are somehow unexpected. In fact, the compound has been shown to bind a pocket located in the C-terminal 
domain of PrPC 17. This region is far from the CR deletion, and opposite from the structural determinants of ΔCR 
PrP activity and Aβ binding sites, which are both located in the unstructured N-terminus. How does binding of 
Fe(III)-TMPyP in the C-terminus block the toxic activities of the PrPC flexible N-terminus? One possibility is 
suggested by several recent studies indicating that the C-terminal and N-terminal domains of PrPC may be func-
tionally coupled, or even directly interact with each other53–56. Therefore, Fe(III)-TMPyP could be acting as an 
allosteric inhibitor of PrPC, blocking the toxic activities elicited by the N-terminal tail. This possibility opens up 
intriguing opportunities to employ Fe(III)-TMPyP not only as a therapeutic agent, but also as an experimental 
tool to study the function of PrPC.
In summary, we have employed multiple biochemical, biophysical and cell-based techniques to demonstrate 
that Fe(III)-TMPyP binds to PrPC, and acts as a strain-independent inhibitor of prion replication. Importantly, we 
also show that the compound blocks the aberrant channel-forming ability of mutant ΔCR PrP, and prevents the 
Figure 6. Treatment with Fe(III)-TMPyP does not alter PrPC expression. (A) HEK293 cells expressing 
ΔCR PrP were treated with Fe(III)-TMPyP at different concentrations, and for the indicated time points. Total 
PrP levels were evaluated in whole-cell lysates by western blot, using anti-PrP antibody 6D11. The picture 
in the upper panel illustrates a Western blot related to the 3 h timepoint. Graph in the bottom panel shows 
the quantification of PrP levels, obtained by densitometric analysis of the Western blots, normalizing each 
value on the corresponding Ponceau S-stained lane. Bars represent the mean of two (20 min) to four (± SEM) 
independent experiments, expressed as percentage of the levels in untreated cells. (B) Hippocampal neurons 
from C57BL/6 mice were exposed to 10 μM Fe(III)-TMPyP (+) or the vehicle (−) for 24 h. Cells were lysed and 
analyzed by Western blot with anti-PrP (6D11) or anti-actin antibodies.
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synaptotoxic effects delivered by Aβ oligomers. These data have important therapeutic implications for prion dis-
eases, and possibly other neurodegenerative conditions. Drug-like, brain-penetrant derivatives of Fe(III)-TMPyP 
may block prion replication and inhibit PrPC-mediated toxicity. Moreover, these compounds could reveal impor-
tant insights into the physiological activity of PrPC, and its functional connection to neurodegenerative pathways.
Methods
Ethics Statement. All experiments involving animals were carried out in accordance with European guide-
lines (Directive 2010/63/EU), and were approved by the animal experimentation ethics committee at CIC bio-
GUNE [in agreement with Article 28, sections a), b), c) and d) of the “Real Decreto 214/1997 de 30 de Julio”]. The 
experiments were also carried out in accordance with the guidelines established by the Italian legislation (L.D. 
no. 26/2014), reviewed by the Animal Welfare Committee of the University of Milan, and approved by the Italian 
Ministry of Health.
Equilibrium dialysis. Compounds were diluted from a 50 mM stock into 1 mM sodium acetate buffer (pH 
5). One hundred microliters of 50 μM Fe(III)-TMPyP, or GN8, were placed in the assay chamber of a 96-Well 
Equilibrium DIALYZER plate (Harvard Apparatus, Holliston, MA), with a 5,000 molecular weight cut-off mem-
brane. One hundred microliters of buffer, 50 μM recombinant PrPC or bovine serum albumin (BSA) were placed 
in the sample chamber. Recombinant PrPC (residues 23–230) was expressed and purified as described previ-
ously57. Samples were left to equilibrate at room temperature for 24 h with slow rocking. The concentration of each 
compound from the assay chamber was quantified using a UV-visible spectrometer (Biotek, Winooski, VT), with 
the appropriate buffer or protein background subtraction.
Dynamic Mass Redistribution (DMR). The EnSight Multimode Plate Reader (Perkin Elmer, Waltham, 
MA) was used to carry out DMR analyses. Immobilization of full-length (residues 23–230), mouse recombinant 
PrPC (15 μL/well of a 2.5 μM PrPC solution in 10 mM sodium acetate buffer, pH 5) on label-free microplates 
(EnSpire-LFB high sensitivity microplates, Perkin Elmer) was obtained by amine-coupling chemistry. The inter-
action between Fe(III)-TMPyP, diluted to different concentrations in assay buffer (10 mM PO4, pH 7.5, 2.4 mM 
KCl, 138 mM NaCl, 0.05% Tween-20) and PrPC, was monitored after a 30 min incubation at room temperature. 
Figure 7. Fe(III)-TMPyP inhibits Aβ oligomer-dependent activation of Fyn. (A) Treatment with Aβ 
oligomers induced a rapid phosphorylation of the Fyn kinase, which was fully prevented by pre-incubation with 
Fe(III)-TMPyP. Primary hippocampal neurons were pre-treated for 20 minutes with Fe(III)-TMPyP (10 μM) 
or vehicle control (volume equivalent) prior to incubation with Aβ oligomers (3 μM, monomer equivalent 
concentration) for 20 minutes. Triton-insoluble fractions were analyzed by immunoblot with antibodies 
against phospho-SFK (Tyr 416) or total Fyn. Actin was used as loading control. The picture shows an example 
of a Western blot for p-Fyn and Fyn. The graph reports the quantification of 5 independent experiments 
(n = 5). Values are expressed as percentage of vehicle (VHC)-treated cells, normalized on the intensity of the 
corresponding Actin bands. *Statistical significance was estimated by one-way ANOVA, Tukey post-hoc test 
(p = 3.77 × 10−4). (B) Neither Aβ , nor Fe(III)-TMPyP altered the phosphorylation of Fyn in PrP-null neurons. 
Primary hippocampal neurons derived from PrP KO mice were pre-treated for 20 minutes with Fe(III)-TMPyP 
(10 μM) or DMSO (volume equivalent) prior to incubation with Aβ oligomers (3 μM, monomer equivalent 
concentration) or vehicle (VHC, volume equivalent) for 20 minutes. Triton-insoluble fractions were analyzed 
by immunoblot with antibodies against phospho-SFK (Tyr 416) or total Fyn. Actin was used as loading 
control. The upper panel shows an example of a Western blot for p-Fyn and total Fyn. The bar graph reports 
the quantification of four independent experiments (n = 4). Values are expressed as percentage of VHC-treated 
cells, normalized on the intensity of the corresponding actin bands.
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All the steps were executed by employing a Zephyr Compact Liquid Handling Workstation (Perkin Elmer). The 
Kaleido software (Perkin Elmer) was used to acquire and process the data.
Surface plasmon resonance (SPR). Binding studies were performed using the ProteOn XPR36 Protein 
Interaction Array system (Bio-Rad, Hercules, CA). The binding of Fe(III)-TMPyP was monitored by immobi-
lizing ~16,000 Resonance Units (RU) of recombinant PrPC on the surface of a sensor chip (GL-H chip, Bio-Rad) 
by amine-coupling chemistry. Compounds were perfused over the chip for 150 sec to allow association, followed 
by a buffer (10 mM PO4, pH 7.5, 2.4 mM KCl, 138 mM NaCl, 0.05% Tween-20) wash to monitor dissociation. 
The resulting sensorgrams (time course of resonance unit signal) were fitted using the ProteOn analysis software 
(Bio-Rad) to obtain the corresponding association and dissociation rate constants (kon and koff, respectively), and 
the equilibrium dissociation constant (Kd).
Western blots. Samples were diluted 1:1 in 2X Laemli sample buffer (2% SDS, 10% glycerol, 100 mM 
Tris-HCl pH 6.8, 0.002% bromophenol blue, 100 mM DTT), heated at 95 °C for 10 min, then analyzed by 
SDS-PAGE. Proteins were electrophoretically transferred to polyvinylidene fluoride (PVDF) membranes, which 
were then blocked for 20 min in 5% (w/v) non-fat dry milk in Tris-buffered saline containing 0.05% Tween-20. 
After incubation with appropriate primary and secondary antibodies, signals were revealed using enhanced 
chemiluminescence (Luminata, BioRad), and visualized by a Bio-Rad XRS Chemidoc image scanner (Bio-Rad).
PMCA. Two different versions of the PMCA reactions were used in this study. The first one was performed as 
described previously24, with minor modifications. Briefly, Tg338 brains used for substrate were perfused using 
PBS/5 mM EDTA, and frozen immediately. A 50 μl aliquot of 10% Tg338 brain homogenate, seeded with different 
dilutions of scrapie (Dawson isolate) were loaded onto 0.2-ml PCR tubes. Samples were incubated with 0.5 μl of 
PBS (not shown), DMSO or Fe(III)-TMPyP (at final concentration of 500 μM) and placed at 37–38 °C into a son-
icating water bath without shaking. Tubes were positioned on an adaptor placed on the plate holder of the soni-
cator (model S-700MPX, QSonica, Newtown, CT, USA), and subjected to cycles of incubation (30 min) followed 
by a 20 s pulse of 150–220 watts sonication (at 70–90% of amplitude) for 48 hr. The detailed protocol for PMCA, 
including reagents, solutions and troubleshooting, has been published elsewhere58.
Figure 8. Fe(III)-TMPyP rescues the synaptotoxic effects of Aβ oligomers. Aβ oligomers induced a loss 
of post-synaptic markers, which was significantly attenuated by pre-incubation with Fe(III)-TMPyP. Primary 
hippocampal neurons were pre-treated for 20 min with or without Fe(III)-TMPyP (10 μM), and exposed for 3 h 
to Aβ oligomers (3 μM) or DMSO vehicle (VHC). Post-synaptic proteins from triton-insoluble fractions were 
then measured by Western blotting. The picture shows a representative Western blot for each synaptic marker. 
Quantitation of multiple experiments is shown in the graph. Actin levels were not significantly affected by Aβ 
oligomer treatment. *Statistical significance. P values, calculated by one-way ANOVA, Tukey post-hoc test, were 
as follow: GluN2A, p = 0.013542; GluN2B, p = 0.010834; GluA1, p = 0.002597; GluA2, p = 0.015558; PSD95, 
p = 0.036794.
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The second PMCA assay was performed as described previously59, with minor modifications. Briefly, 
PMCA substrates were prepared using 2–3 month-old bank voles homozygous for methionine at codon 109 
(Bv109M). Perfused brains were immediately homogenized in Conversion Buffer (PBS 1×, pH 7,4; 0.15 M 
NaCl; 1% Triton X) with mini-Complete protease inhibitor (Roche) as 10% w/v, and then stored at − 80 °C. 
Fe(III)-TMPyP (1–500 μM) or vehicle control were added to the PMCA substrate just prior to the in vitro ampli-
fication experiment. Seeds were prepared using brain tissue from Bv109M terminally affected with three different 
Bv109M-adapted PrPSc strains, namely Italian, UK and CH1641, derived from the Italian sheep PrPSc isolate 
SS7, the UK sheep PrPSc isolate SCR125, and the experimental PrPSc isolate CH164126. Tissues were homoge-
nized in PBS (10% w/v), diluted 1:10 and 1:100 in PMCA substrate and either frozen at − 20 °C or immediately 
subjected to PMCA. Samples were processed for 32 continuous cycles of PMCA, consisting of 20 s pulse son-
ication at 80% power output using a Misonix S3000 sonicator, followed by incubation for 30 min at 37 °C. All 
samples were analyzed by PK digestion and Western Blotting as previously reported60. Blots were probed with 
anti-PrP monoclonal antibody SAF84 (a.a. 167–173 Bank vole PrP sequence; 1.2 μg/mL), followed by horse-
radish peroxidase-conjugated anti-mouse immunoglobulin (Pierce Biotechnology, Rockford, IL). Proteinase K 
(PK)-resistant PrP bands were visualized using the chemiluminescence method (SuperSignal Femto, Pierce), 
detected by the VersaDoc imaging system (Bio-Rad) and quantified by QuantityOne software (Bio-Rad). The 
amplification factor was calculated by quantifying the amount of PrPSc in post-PMCA 1:100 diluted samples (Y) 
and in the 1:10 frozen dilution (X), taking into account the different dilution factor within the two, using the 
formula (Y/X) × 10. The amplification factor was then calculated as the mean value (± standard deviation) of 
independent samples.
Prion-infected neuroblastoma cells. N2a cells (a subclone of N2a cells infected with the 22L prion strain) 
were propagated for 5–7 passages to stabilize PrPSc levels. Cells were grown in culturing medium [Dulbecco’s 
Minimal Essential Media (DMEM), 10% heat-inactivated fetal bovine serum (Δ56-FBS), Non-Essential Amino 
Acids (NEAA) and Penicillin/Streptomycin (Pen/Strep)]. To test anti-prion activity of Fe(III)-TMPyP, cells were 
plated on day 1 in 24-well plates at approximately 60% confluence, in presence or absence of relevant compound 
(usually at concentrations between 0.1 and 10 μM). On days 2 and 4, 100% medium was changed, adding fresh 
compound. On day 3, each well was split 1:2 in medium containing fresh compound. In order to avoid the use of 
trypsin, cells were detached by adding medium directly onto the surface of the well, and mechanically dissociated 
by pipetting gently for 10–15 times. On day 5, cells were collected by adding 100 μl (per well) of lysis buffer (PBS, 
pH 7.4, 0.5% NP-40, 0.5% TX-100, plus complete EDTA-free Protease Inhibitor Cocktail Tablets, Roche) directly 
into the well. Proteinase-K (PK) digestion was performed by incubating 100 μl of lysate in a shaking (450 rpm) 
thermomixer for 1 h at 37 °C with 10 μg/ml of PK. The reaction was stopped by adding 2 mM PMSF, followed by 
methanol (MeOH) precipitation (10:1 volume ratio of MeOH to sample; each sample incubated for 4 h at − 80 °C 
and then centrifuged at 14.000 rpm × 20 min at 4 °C). The resulting pellet (dried at room temperature to remove 
any residual MeOH) was boiled in Laemli sample buffer, and subjected to Western blotting. Blots were probed 
with 6D11 antibody (1:4000) followed by goat anti-mouse IgG (Pierce), and signals were revealed using enhanced 
chemiluminescence (Luminata, BioRad) and visualized by a Biorad XRS image scanner.
Patch clamping of HEK293 cells. The spontaneous ion channel activity induced by the ΔCR PrP mutant 
in HEK293 cells was detected by whole-cell patch clamping as previously described61,62. Borosilicate electrodes 
with an electrical resistance of 3–6 MΩ were used. Cells were visualized with the 40X objectives using an Olympus 
BX51WI microscope equipped with reflected fluorescence, as well as differential interference contrast observa-
tion systems. Experiments were conducted at room temperature with the following solutions: Internal: 140 mM 
Cs-glucuronate, 5 mM CsCl, 4 mM MgATP, 1 mM Na2GTP, 10 mM EGTA, and 10 mM HEPES (pH 7.4 with 
CsOH); External: 150 mM NaCl, 4 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM glucose, and 10 mM HEPES 
(pH 7.4 with NaOH). Data were acquired using a Multiclamp 700B amplifier and pClamp 10 software (Molecular 
Devices, Foster City, CA), and sampled at 5 kHz with a Digidata 1440 (Molecular Devices). Data were analyzed 
off-line using the Clampfit 10 software (Molecular Devices).
Drug-Based Cell Assay (DBCA). The DBCA was performed as described previously29, with minor modi-
fications. Briefly, HEK293 cells expressing ΔCR PrP were cultured at ~60% confluence in 24-well plates on day 1. 
On day 2, cells were treated with 500 μg/mL of Zeocin and/or Fe(III)-TMPyP (0.1–10 μM) for 72 hr. Medium 
(containing fresh Zeocin and/or Fe(III)-TMPyP) was replaced every 24 hr. On day 5, cell medium was removed 
and cells were incubated with 1 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT, Sigma Aldrich, St. Louis, MO) in PBS for 30 min at 37 °C. MTT was carefully removed, and cells were 
re-suspended in 500 μL of DMSO. Values for each well were obtained by measuring at 570 nm, using a plate spec-
trophotometer (Biotek).
Preparation of Aβ oligomers. Synthetic Aβ (1–42) peptide (Karebay Biochem., Rochester, NY) was 
dissolved in hexafluoro-2-propanol, incubated for 10 min in a bath sonicator at maximum power, centrifuged 
at 15.000 × g for 1 min, aliquoted, dried, and stored at − 80 °C. Before use, the dried film was dissolved using 
DMSO and diluted to 100 μM in F12 Medium (Invitrogen, Waltham, MA). Oligomers were obtained by incu-
bating the peptide for 16 h at 25 °C. This preparation routinely produces oligomers that elute near the void vol-
ume of a Superdex 75 10/300 size exclusion column (GE Healthcare, Little Chalfont, UK), and that react with 
oligomer-specific antibody A1133. Final Aβ oligomer concentrations were considered as monomer equivalents, 
since the size of the oligomers is heterogeneous.
Cultured hippocampal neurons. Primary neuronal cultures were derived from the hippocampi of 
2-day-old postnatal mice, and cultured as described previously63. Neurons were plated on 35-mm dishes (500,000 
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cells/dish) pre-coated with 25 μg/mL poly-D-lysine (Sigma P6407) in B27/Neurobasal-A medium supplemented 
with 0.5 mM glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin (all from Invitrogen). Experiments 
were performed 12 days after plating. Neurons were pre-treated for 20 min with Fe(III)-TMPyP (10 μM) and then 
exposed for 20 mins or 3 hr to Aβ oligomers (3 μM). Triton-insoluble fractions (TIF) were analyzed by immunob-
lot with antibodies against phospho-SFK (Tyr 416) or Fyn. The phospho-SFK antibody detects pY416 in several 
SFKs, but previous studies showed that PrPC-dependent activation of kinases is specific for Fyn. Actin was used 
as loading control. Subcellular fractionation was performed as reported previously, with minor modifications. 
Neurons were homogenized using a Potter-Elvehjem homogenizer in 0.32 M ice-cold sucrose buffer (pH 7.4) con-
taining 1 mM HEPES, 1 mM MgCl2, 10 mM NAF, 1 mM NaHCO3, and 0.1 mM PMSF in the presence of protease 
inhibitors (Complete mini, Roche Applied Science, Penzberg, Germany) and phosphatase inhibitors (PhosSTOP, 
Roche Applied Science). Samples were centrifuged at 13.000 × g for 15 min to obtain a crude membrane frac-
tion. The pellet was re-suspended in buffer containing 150 mM KCl and 0.5% Triton X-100 and centrifuged at 
100,000 × g for 1 hr. The final pellet, referred to as the Triton-insoluble fraction, was re-homogenized in 20 mM 
HEPES supplemented with protease and phosphatase inhibitors and then stored at − 80 °C or directly used in 
further experiments. Protein concentration in each sample was quantified using the Bradford assay (Bio-Rad), 
and proteins (5 μg) were then analyzed by Western blotting. Primary antibodies were as follow: anti-GluN2A 
and anti-GluN2B (both 1:2000; Invitrogen), anti-GluA1 and anti-GluA2 (both 1:1000; Millipore, Billerica, MA), 
anti-PSD-95 (post-synaptic density protein 95; 1:2000; Cayman Chemical, Ann Arbor, MI), and anti-actin 
(1:5000; Millipore). Western blots were analyzed by densitometry using Quantity One software (Bio-Rad). All 
experiments were repeated on at least 4 independent culture preparations (n = 4).
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